Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 2306-2310

  Kaya, Mehmet G ^a   Ozkan, Metin ^a   Gunebakmaz, Ozgur ^a   Akkaya, Hasan ^a   Kaya, Esma G ^b   Akpek, Mahmut ^a   Kalay, Nihat ^a   Dikilitas, Mustafa ^a   Yarlioglues, Mikail ^a   Karaca, Halit ^a   Berk, Veli ^a   Ardic, Idris ^a   Ergin, Ali ^a   Lam, Yat Yin ^c  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anthracycline; Cardiomyopathy; Nebivolol

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; NEBIVOLOL; PLACEBO;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART PROTECTION; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTHRACYCLINE; CARDIOMYOPATHY; NEBIVOLOL;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84883271396     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.06.023     Document Type: Article

References (35)

1. K.J. Schimmel, D.J. Richel, R.B. van den Brink, and H.J. Guchelaar Cardiotoxicity of cytotoxic drugs Cancer Treat Rev 30 2004 181 191
2. H.H. Chao, J.C. Liu, H.J. Hong, J.W. Lin, C.H. Chen, and T.H. Cheng L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin- mediated pathway in neonatal rat cardiomyocytes Int J Cardiol 146 2011 145 152
3. J. Zhang, J.R. Clark, E.H. Herman, and V.J. Ferrans Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187 Am J Pathol 142 1993 1916 1926
4. A. Saraste, K. Pulkki, and M. Kallajoki Cardiomyocyte apoptosis and progression of heart failure to transplantation Eur J Clin Invest 29 1999 380 386
5. S. Zhou, A. Starkov, M.K. Froberg, R.L. Leino, and K.B. Wallace Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin Cancer Res 61 2001 771 777
6. K. Becker, J.F. Erckenbrecht, D. Häussinger, and T. Frieling Cardiotoxicity of the antiproliferative compound fluorouracil Drugs 57 1999 475 484
7. R.T. Dorr Chemoprotectants for cancer chemotherapy Semin Oncol 18 1991 48 58
8. C. Myers, R. Bonow, and S. Palmeri A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine Semin Oncol 10 1983 53 55
9. K. Okumura, D. Jin, S. Takai, and M. Miyazaki Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters Jpn J Pharmacol 88 2002 183 188
10. M. Iqbal, K. Dubey, T. Anwer, A. Ashish, and K.K. Pillai Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats Pharmacol Rep 60 2008 382 390
11. H. Matsui, I. Morishima, Y. Numaguchi, Y. Toki, K. Okumura, and T. Hayakawa Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats Life Sci 65 1999 1265 1274
12. F. de Nigris, M. Rienzo, C. Schiano, C. Fiorito, A. Casamassimi, and C. Napoli Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart Eur J Cancer 44 2008 334 340
13. X. Chen, Y. Chen, and Y. Bi Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy Cardiovasc Drugs Ther 21 2007 367 374
14. S. Bien, A. Riad, and C.A. Ritter The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy Cancer Res 67 2007 10428 10435
15. D.S. Kim, S.W. Chae, H.R. Kim, and H.J. Chae CO and bilirubin inhibit doxorubicin-induced cardiac cell death Immunopharmacol Immunotoxicol 31 2009 64 70
16. L.J. Ignarro, G. Cirino, A. Casini, and C. Napoli Nitric oxide as a signaling molecule in the vascular system: an overview J Cardiovasc Pharmacol 34 1999 879 886
17. R.P. Mason, L. Kalinowski, R.F. Jacob, A.M. Jacoby, and T. Malinski Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans Circulation 112 2005 3795 3801
18. R.M. Lang, M. Bierig, and R.B. Devereux American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification Eur J Echocardiogr 7 2006 79 108
19. C. Tei, L.H. Ling, and D.O. Hodge New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy J Cardiol 26 1995 357 366
20. T. Lieutaud, E. Brain, and D. Golgran-Toledano 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 32 1996 368 369
21. A. Tiersten, J. Wo, and C. Jacobson Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer Breast 13 2004 341 346
22. T.C. Liu, S. Ismail, O. Brennan, C. Hastings, and G.P. Duffy Encapsulation of cardiac stem cells in superoxide dismutase-loaded alginate prevents doxorubicin-mediated toxicity J Tissue Eng Regen Med 4 2013 302 311
23. O.J. Arola, A. Saraste, K. Pulkki, M. Kallajoki, M. Parvinen, and L.M. Voipio-Pulkki Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis Cancer Res 60 2000 1789 1792
24. W.J. Gradishar Vokes EE 5-Fluorouracil cardiotoxicity: a critical review Ann Oncol 1 1990 409 414
25. P.K. Singal, N. Iliskovic, T. Li, and D. Kumar Adriamycin cardiomyopathy: pathophysiology and prevention FASEB J 11 1997 931 936
26. C.G. Tocchetti, G. Ragone, and C. Coppola Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge Eur J Heart Fail 14 2012 130 137
27. M.N. Levine, V.H. Bramwell, and K.I. Pritchard Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 1998 2651 2658
28. M. Ryberg, D. Nielsen, T. Skovsgaard, J. Hansen, B.V. Jensen, and P. Dombernowsky Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer J Clin Oncol 16 1998 3502 3508
29. Y. Mukai, T. Yoshida, and R. Nakaike Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol Intern Med 43 2004 1087 1088
30. The MERIT-HF study group Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trail in congestive heart failure (MERIT-HF) Lancet 353 1999 9 13
31. S. Fazio, E.A. Palmieri, B. Ferravante, F. Bonè, B. Biondi, and L. Saccà Doxorubicin-induced cardiomyopathy treated with carvedilol Clin Cardiol 21 1998 777 779
32. N. Kalay, E. Basar, and I. Ozdogru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
33. M.C. Shibata, M.D. Flather, and M. Bohm Study of the effect of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure (SENIORS). Rationale and design Inter J Cardiol 86 2002 77 85
34. T. Munzel, and T. Gori Nebivolol: The somewhat-different beta-adrenergic receptor blocker J Am Coll Cardiol 54 2009 1491 1499
35. A.A. de Groot, M.J. Mathy, P.A. van Zwieten, and S.L. Peters Antioxidant activity of nebivolol in the rat aorta J Cardiovasc Pharmacol 43 2004 148 153